Brokerages Set Liquidia Co. (NASDAQ:LQDA) Price Target at $21.60

Shares of Liquidia Co. (NASDAQ:LQDA) have been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have given a buy rating to the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $21.60.

A number of research firms recently weighed in on LQDA. Oppenheimer began coverage on Liquidia in a report on Tuesday, June 25th. They issued a “market perform” rating for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price target on shares of Liquidia in a report on Thursday, July 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $32.00 price objective on shares of Liquidia in a research note on Wednesday, July 10th.

Insiders Place Their Bets

In other news, CEO Roger Jeffs sold 8,053 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $100,904.09. Following the completion of the sale, the chief executive officer now directly owns 818,932 shares in the company, valued at $10,261,217.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other news, CFO Michael Kaseta sold 3,906 shares of the company’s stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $48,942.18. Following the completion of the sale, the chief financial officer now directly owns 312,389 shares in the company, valued at $3,914,234.17. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction that occurred on Friday, July 12th. The stock was sold at an average price of $12.53, for a total value of $100,904.09. Following the completion of the transaction, the chief executive officer now owns 818,932 shares of the company’s stock, valued at $10,261,217.96. The disclosure for this sale can be found here. In the last three months, insiders sold 19,604 shares of company stock worth $247,579. Corporate insiders own 31.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LQDA. Vanguard Group Inc. grew its position in Liquidia by 1.0% in the third quarter. Vanguard Group Inc. now owns 2,774,398 shares of the company’s stock worth $17,590,000 after acquiring an additional 26,678 shares during the period. Fortitude Family Office LLC purchased a new position in Liquidia in the fourth quarter worth approximately $26,000. SG Americas Securities LLC grew its position in Liquidia by 17.4% in the fourth quarter. SG Americas Securities LLC now owns 15,540 shares of the company’s stock worth $187,000 after acquiring an additional 2,298 shares during the period. Bleakley Financial Group LLC grew its position in Liquidia by 45.6% in the fourth quarter. Bleakley Financial Group LLC now owns 31,193 shares of the company’s stock worth $375,000 after acquiring an additional 9,764 shares during the period. Finally, LB Partners LLC acquired a new position in Liquidia during the fourth quarter worth $3,404,000. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Stock Down 1.8 %

Shares of LQDA stock opened at $11.34 on Friday. The stock has a market cap of $866.53 million, a PE ratio of -7.27 and a beta of 0.32. Liquidia has a 52-week low of $5.71 and a 52-week high of $16.99. The business has a 50-day simple moving average of $12.62 and a 200-day simple moving average of $13.42.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Monday, May 13th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.22). The business had revenue of $2.97 million during the quarter, compared to analyst estimates of $4.31 million. Liquidia had a negative return on equity of 177.83% and a negative net margin of 674.42%. Sell-side analysts anticipate that Liquidia will post -1.32 earnings per share for the current fiscal year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).